The clinical investigator

, Volume 71, Issue 5, pp 383–386

Effects of garlic coated tablets in peripheral arterial occlusive disease

  • H. Kiesewetter
  • F. Jung
  • E.M. Jung
  • J. Blume
  • C. Mrowietz
  • A. Birk
  • J. Koscielny
  • E. Wenzel
Original Article

Summary

For the first time, a weak clinical efficacy of a 12-week therapy with garlic powder (daily dose, 800 mg) is demonstrated in patients with peripheral arterial occlusive disease stage II. The increase in walking distance in the verum group by 46 m (from 161.0 ± 65.1 to 207.1 ± 85.0 m) was significantly higher (P<0.05) than in the placebo group (by 31 m, from 172.0 ± 60.9 to 203.1 ± 72.8). Both groups received physical therapy twice a week. The diastolic blood pressure, spontaneous thrombocyte aggregation, plasma viscosity, and cholesterol concentration also decreased significantly. Body weight was maintained. It is quite interesting that the garlic-specific increase in walking distance did not appear to occur until the 5th week of treatment, connected with a simultaneous decrease in spontaneous thrombocyte aggregation. Therefore, garlic may be an appropriate agent especially for the long-term treatment of an incipient intermittent claudication.

Key words

Peripheral arterial occlusive disease Garlic powder Kwai® Sapec® 

Abbreviation

PAOD

peripheral arterial occlusive disease

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alström T, Grdsbeck R, Hjelm M, Skandsen S (1975) Recommendations concerning the collection of reference values in clinical chemistry and activity report. Scand J Clin Lab Invest 35:1–43Google Scholar
  2. 2.
    Bauer U (1984) 6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneimittelforschung 34:110–114Google Scholar
  3. 3.
    Bents H, Buchkremer G (1987) Raucherentwöhnung. Psychologische und pharmakologische Methoden. Dtsch Med Wochenschr 112:559–564Google Scholar
  4. 4.
    Bollinger A, Frei C (1977) Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1:557Google Scholar
  5. 5.
    Bordia AK, Joshi HK, Sanadhya YK, Bhu N (1977) Effect of essential oil of garlic on serum fibrinolytic activity in patients with coronary artery disease. Atherosclerosis 28:155–159Google Scholar
  6. 6.
    Boullin DJ (1981) Garlic as a platelet inhibitor. Lancet 4:776–777Google Scholar
  7. 7.
    Breddin K, Grun H, Krzywanek HJ, Schremmer MM (1975) On the measurement of spontaneous thrombocyte aggregation. The platelet aggregation. II. Methods and first clinical results. Thromb Haemost 48:261–272Google Scholar
  8. 8.
    Chutani SK, Bordia A (1981) The effect of fried versus raw garlic on fibrinolytic activity in man. Atherosclerosis 38:417–421Google Scholar
  9. 9.
    Foushee DB, Ruffin J, Banerjee U (1982) Garlic as a natural agent for the treatment of hypertension: a preliminary report. Cytobios 34:145–152Google Scholar
  10. 10.
    Heidrich H, Boccalon HJL (1986) Prinzipien kontrollierter klinischer Therapiestudien bei peripherer arterieller Verschlußkrankheit. Angio Archiv 13:17–21Google Scholar
  11. 11.
    Jung F, Kiesewetter H, Roggenkamp HG, Nüttgens HP, Ringelstein EB, Gerhards M, Kotitschke G, Wenzel E, Zeller H (1986) Bestimmung der Referenzbereiche rheologischer Parameter: Studie an 653 zufällig ausgewählten Probanden im Kreis Aachen. Klin Wochenschr 64:375–381Google Scholar
  12. 12.
    Jung F, Wolf S, Kiesewetter H, Mrowietz C, Pindur G, Heiden M, Myashita C, Wenzel E, Reim M (1989) Wirkung von Knoblauch auf die Fließfähigkeit des Blutes. Ergebnisse placebo-kontrollierter Pilotstudien an gesunden Probanden. Natur- and Ganzheitsmedizin 7:216–221Google Scholar
  13. 13.
    Krause D, Dittmar K (1976) Kombination krankengymnastischer Übungen mit Bencyclan bei Claudicatio intermittens. Münchner Med Wochenschr 118:1281–1284Google Scholar
  14. 14.
    Maass U, Amberger HG, Böhme H, Diehm C, Dimroth H, Heidrich H, Heinrich F, Hirche H, Mörl H, Müller-Bühil U, Rudosky G, Trübestein R, Trübestein G (1984) Naftidrofuryl bei arterieller Verschlußkrankheit. Kontrollierte multizentrische Doppelblindstudie mit oraler Applikation. Dtsch Med Wochenschr 109:745Google Scholar
  15. 15.
    Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, Strandness DE (1982) Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104:66Google Scholar
  16. 16.
    Sainani GS, Desai DB, Gorhe NH, Natu SM, Pise DV, Sainani PG (1979) Effect of dietary garlic and onion on serum lipid profile in Jain community. Indian J Med Res 69:776–780Google Scholar
  17. 17.
    Schraeder R (1984) Wirksamkeit von Padma 28 auf die Claudicatio intermittens bei chronisch peripherer arterieller Verschlußkrankheit. University of Berne, thesisGoogle Scholar
  18. 18.
    Trampisch HJ (1986) Statistische Basis für kontrollierte klinische Studien bei peripherer-arterieller Verschlußkrank-heit. Angio Archiv 13:9–13Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • H. Kiesewetter
    • 1
    • 3
  • F. Jung
    • 1
  • E.M. Jung
    • 1
  • J. Blume
    • 2
  • C. Mrowietz
    • 1
  • A. Birk
    • 2
  • J. Koscielny
    • 1
  • E. Wenzel
    • 1
  1. 1.Abteilung für Klinische Hämostaseologie and TransfusionsmedizinUniversität des SaarlandesHomburg/SaarGermany
  2. 2.Zentrum für Gefäß- und KreislauferkrankungenAachenGermany
  3. 3.Abteilung für Klinische Hämostaseologie und TransfusionsmedizinUniversität des SaarlandesHomburg/SaarGermany

Personalised recommendations